Cronos (CRON)
Market Price (12/27/2025): $2.7 | Market Cap: $1.0 BilSector: Health Care | Industry: Pharmaceuticals
Cronos (CRON)
Market Price (12/27/2025): $2.7Market Cap: $1.0 BilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -81% | Weak multi-year price returns2Y Excs Rtn is -6.7%, 3Y Excs Rtn is -81% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -24 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -18% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 16% | Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 47x, P/EPrice/Earnings or Price/(Net Income) is 28x | |
| Low stock price volatilityVol 12M is 47% | Not cash flow generativeFCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -4.3% | |
| Megatrend and thematic driversMegatrends include Cannabis & Psychedelics. Themes include Medical Cannabis, Recreational Cannabis, and CBD & Wellness Products. | Key risksCRON key risks include [1] persistent unprofitability and cash burn stemming from operational inefficiencies, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -81% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 16% |
| Low stock price volatilityVol 12M is 47% |
| Megatrend and thematic driversMegatrends include Cannabis & Psychedelics. Themes include Medical Cannabis, Recreational Cannabis, and CBD & Wellness Products. |
| Weak multi-year price returns2Y Excs Rtn is -6.7%, 3Y Excs Rtn is -81% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -24 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -18% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 47x, P/EPrice/Earnings or Price/(Net Income) is 28x |
| Not cash flow generativeFCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -4.3% |
| Key risksCRON key risks include [1] persistent unprofitability and cash burn stemming from operational inefficiencies, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
<b>1. Cronos Group reported strong Q2 2025 financial results.</b> The company's net revenue increased by 21% year-over-year to $33.5 million, with a gross margin of 43% and positive Adjusted EBITDA of $1.7 million. They also maintained a robust balance sheet with $834 million in cash and short-term investments.
<br><br>
<b>2. The company announced positive Q3 2025 financial results.</b> Cronos Group reported net revenue of $36.3 million, a 6% increase year-over-year and 9% sequentially. Gross profit rose to $18.3 million, and Adjusted EBITDA was positive at $5.7 million. These results were driven by record sales in Israel, where PEACE NATURALS® remained the top cannabis brand, and a strong liquidity position with $824 million in cash and short-term investments.
<br><br>
<b>3. Cronos Group strategically expanded into the European market with an acquisition.</b> On December 9, 2025, Cronos announced a definitive agreement to acquire CanAdelaar B.V., the largest company in the Netherlands' adult-use cannabis pilot. This acquisition, for an upfront cash consideration of US$67.0 million, is anticipated to give Cronos a leading market share in a significant European adult-use cannabis market.
<br><br>
<b>4. Several new product launches and brand expansions occurred.</b> During the period, Cronos launched SOURZ by Spinach® Fully Blasted Multipacks on October 9, 2025, and expanded its premium Lord Jones® brand with Live Resin Fusions™ in Canada on November 25, 2025. The company also brought back popular, limited-edition Spinach® Green Apple-flavored products on October 28, 2025.
<br><br>
<b>5. Analyst sentiment and recent stock performance indicated mixed views.</b> As of December 19, 2025, Cronos stock was trading at $2.97 USD, experiencing a modest recent decline of 0.02%. While the company showed revenue growth of 6.10% and positive EPS, it also faced challenges with a negative free cash flow of $21.7 million. Analyst ratings were divided, with an average target price suggesting a potential downside, yet technical indicators showed a bullish trend.
Show moreStock Movement Drivers
Fundamental Drivers
The 1.1% change in CRON stock from 9/26/2025 to 12/26/2025 was primarily driven by a 92.2% change in the company's Net Income Margin (%).| 9262025 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 2.63 | 2.66 | 1.14% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 130.28 | 132.36 | 1.59% |
| Net Income Margin (%) | 14.19% | 27.27% | 92.18% |
| P/E Multiple | 54.81 | 28.23 | -48.50% |
| Shares Outstanding (Mil) | 385.31 | 383.09 | 0.58% |
| Cumulative Contribution | 1.14% |
Market Drivers
9/26/2025 to 12/26/2025| Return | Correlation | |
|---|---|---|
| CRON | 1.1% | |
| Market (SPY) | 4.3% | 21.4% |
| Sector (XLV) | 15.2% | -5.7% |
Fundamental Drivers
The 40.0% change in CRON stock from 6/27/2025 to 12/26/2025 was primarily driven by a 91.8% change in the company's P/E Multiple.| 6272025 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 1.90 | 2.66 | 40.00% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 124.59 | 132.36 | 6.23% |
| Net Income Margin (%) | 39.68% | 27.27% | -31.28% |
| P/E Multiple | 14.72 | 28.23 | 91.82% |
| Shares Outstanding (Mil) | 382.96 | 383.09 | -0.03% |
| Cumulative Contribution | 40.00% |
Market Drivers
6/27/2025 to 12/26/2025| Return | Correlation | |
|---|---|---|
| CRON | 40.0% | |
| Market (SPY) | 12.6% | 16.1% |
| Sector (XLV) | 17.0% | -6.7% |
Fundamental Drivers
The 32.3% change in CRON stock from 12/26/2024 to 12/26/2025 was primarily driven by a 19.0% change in the company's Total Revenues ($ Mil).| 12262024 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 2.01 | 2.66 | 32.34% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 111.23 | 132.36 | 19.00% |
| P/S Multiple | 6.91 | 7.70 | 11.45% |
| Shares Outstanding (Mil) | 382.29 | 383.09 | -0.21% |
| Cumulative Contribution | 32.34% |
Market Drivers
12/26/2024 to 12/26/2025| Return | Correlation | |
|---|---|---|
| CRON | 32.3% | |
| Market (SPY) | 15.8% | 27.7% |
| Sector (XLV) | 13.3% | 12.7% |
Fundamental Drivers
The 6.8% change in CRON stock from 12/27/2022 to 12/26/2025 was primarily driven by a 59.5% change in the company's Total Revenues ($ Mil).| 12272022 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 2.49 | 2.66 | 6.83% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 82.97 | 132.36 | 59.53% |
| P/S Multiple | 11.35 | 7.70 | -32.16% |
| Shares Outstanding (Mil) | 378.11 | 383.09 | -1.32% |
| Cumulative Contribution | 6.81% |
Market Drivers
12/27/2023 to 12/26/2025| Return | Correlation | |
|---|---|---|
| CRON | 31.0% | |
| Market (SPY) | 48.0% | 23.8% |
| Sector (XLV) | 18.2% | 17.0% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CRON Return | -10% | -44% | -35% | -18% | -3% | 36% | -64% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 150% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 114% |
Monthly Win Rates [3] | |||||||
| CRON Win Rate | 42% | 25% | 25% | 33% | 33% | 58% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| CRON Max Drawdown | -41% | -45% | -36% | -34% | -11% | -20% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)
How Low Can It Go
| Event | CRON | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -89.3% | -25.4% |
| % Gain to Breakeven | 831.1% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -47.1% | -33.9% |
| % Gain to Breakeven | 89.2% | 51.3% |
| Time to Breakeven | 263 days | 148 days |
| 2018 Correction | ||
| % Loss | -74.1% | -19.8% |
| % Gain to Breakeven | 286.0% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
Cronos's stock fell -89.3% during the 2022 Inflation Shock from a high on 2/10/2021. A -89.3% loss requires a 831.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Here are 1-3 brief analogies for Cronos (CRON):
- Altria for cannabis: CRON is a cannabis company that has received significant strategic investment and backing from tobacco giant Altria (MO), positioning it as a major player in the emerging, regulated cannabis market with established industry support.
- Procter & Gamble of cannabis brands: CRON aims to build and manage a diversified portfolio of consumer-facing cannabis brands across various product categories, much like Procter & Gamble (PG) does with household and personal care brands.
AI Analysis | Feedback
- Cannabis Flower: Dried cannabis buds cultivated for smoking or vaporization.
- Pre-rolls: Ready-to-use cannabis joints, typically made from ground cannabis flower.
- Vape Products: Vaporizable cannabis extracts in cartridges or disposable vape pens.
- Edibles: Food and beverage products infused with cannabis cannabinoids.
- Concentrates: Highly potent cannabis extracts like oils, shatter, and wax.
- Topicals: Cannabis-infused creams, balms, and lotions designed for external application.
- CBD Products: A range of non-psychoactive cannabidiol (CBD) products, including oils, capsules, and topicals.
AI Analysis | Feedback
Cronos Group (CRON) - Major Customers
Cronos Group primarily operates in a business-to-business (B2B) model, selling its cannabis and cannabis-derived products to other companies rather than directly to individual consumers. Its major customers are governmental provincial cannabis boards and distributors in Canada, which then supply licensed retailers and/or operate their own retail channels.
According to their financial filings, a significant portion of Cronos Group's consolidated net revenue comes from a limited number of these governmental provincial cannabis boards/distributors in Canada. These entities are not publicly traded companies and therefore do not have stock symbols.
Major Customers (Examples of Provincial Cannabis Boards/Distributors in Canada):
- Ontario Cannabis Store (OCS): The sole wholesale distributor of recreational cannabis to private retailers in Ontario, and the only legal online retailer for recreational cannabis in the province.
- Société québécoise du cannabis (SQDC): The exclusive legal retailer of recreational cannabis in Quebec, operating both retail stores and an online platform, and also serving as the distributor within the province.
- BC Liquor Distribution Branch (BCLDB - Cannabis Operations): Responsible for the wholesale distribution of cannabis to licensed retailers and for operating government-run cannabis stores and online sales in British Columbia.
- Alberta Gaming, Liquor & Cannabis (AGLC): Oversees the private retail model for cannabis in Alberta, acting as the sole wholesaler for cannabis products in the province.
AI Analysis | Feedback
- Ginkgo Bioworks Holdings, Inc. (DNA)
AI Analysis | Feedback
Mike Gorenstein, Chairman, President and Chief Executive Officer
Mike Gorenstein is the Chairman, President, and Chief Executive Officer of Cronos Group, a position he has held since March 2022, having previously served in the role until September 2020. He is also a Co-Founder and passive Member of Gotham Green Partners. Before joining Cronos, he was the Vice President and General Counsel at Alphabet Partners, LP, a New York City-based multi-strategy investment management firm. Prior to Alphabet Partners, LP, he worked as a corporate attorney at Sullivan & Cromwell LLP, where he focused on mergers and acquisitions and capital markets transactions.
Anna Shlimak, Chief Financial Officer
Anna Shlimak was appointed Chief Financial Officer of Cronos Group in March 2025. She has been an integral part of Cronos' leadership team for seven years, previously serving as Chief Strategy Officer. In her prior role, she was responsible for managing the company's corporate strategy, investor relations, communications, government affairs, and information systems departments, and has been credited with leading strategic initiatives including cost optimization and revenue growth. Before joining Cronos, Shlimak served as the Head of Investor Relations at Quest Partners LLC, a research-driven alternative investment firm, and held various positions at the New York Stock Exchange.
Jeff Jacobson, Chief Growth Officer
Jeff Jacobson was appointed Chief Growth Officer of Cronos Group in October 2022. He has been with Cronos since December 2016, previously holding roles as Senior Vice President, Head of Growth (North America), and General Manager of Canada and Europe. Mr. Jacobson co-founded Peace Naturals, and his expertise includes licensing and compliance, new business development, project management, and resource management. Before his time at Cronos, he founded a marketing agency in Toronto and successfully launched and licensed several software products in the mobile industry.
Shannon Buggy, Senior Vice President and Global Head of People
Shannon Buggy serves as the Senior Vice President and Global Head of People at Cronos Group. She is a key member of the leadership team, responsible for people management within the company.
Terry Doucet, General Counsel and Corporate Secretary
Terry Doucet is Cronos Group's General Counsel and Corporate Secretary, managing all legal and regulatory affairs for the company. Prior to joining Cronos, he was a corporate lawyer at Davies Ward Phillips & Vineberg LLP in Toronto, where he focused primarily on mergers and acquisitions, securities, corporate finance, and lending transactions. He also completed a secondment to RBC Capital Markets.
AI Analysis | Feedback
The Cronos Group (CRON) faces several key risks to its business, primarily stemming from the evolving and complex cannabis industry landscape. The most significant risks include:
-
Regulatory and Legal Uncertainty
The cannabis industry operates under a highly uncertain regulatory environment, particularly in the United States, where cannabis remains illegal at the federal level despite state-level legalization. This federal prohibition significantly restricts Cronos Group's ability to fully access and operate in the potentially lucrative U.S. market and list on major U.S. exchanges. A major factor is the ongoing discussion and potential delays or rejection of marijuana rescheduling to Schedule III in the U.S., which could profoundly impact the company's stock value and operational flexibility. Furthermore, the company faces challenges with Canadian cannabis regulations, including excise taxes and physical tax stamps, which can hinder competitiveness against the illicit market. International trade disputes and tariffs, as seen with past concerns over potential tariffs on Canadian cannabis in Israel, also pose ongoing risks to global operations and profitability.
-
Profitability and Cash Flow Challenges
Despite holding a substantial cash reserve, Cronos Group has struggled with consistent profitability and remains in a "cash-burn phase". The company has reported negative profitability margins, including negative EBIT and pre-tax profit margins, indicating challenges in achieving overall profitability. This ongoing struggle is further highlighted by negative free cash flow, which could impede the company's ability to reinvest in growth initiatives or effectively manage its financial obligations in the long term. Operational inefficiencies and weak cost management have also been cited as contributing factors to these profitability concerns.
-
Supply Constraints, Market Competition, and Regional Revenue Reliance
Cronos Group has experienced operational challenges such as supply constraints, particularly for premium flower products within the Canadian market, leading to temporary declines in sales. The Canadian market is characterized as mature and highly competitive, intensifying pressure on the company. A significant portion of Cronos Group's revenue growth is driven by international markets, specifically Israel, making the company's growth highly regional and susceptible to market-specific risks in those areas. The competition with the illicit cannabis market in Canada also continues to pose a challenge to sales and market share.
AI Analysis | Feedback
The accelerated consolidation and market entrenchment of U.S. multi-state operators (MSOs) while federal cannabis prohibition persists represents a clear emerging threat to Cronos. These MSOs are rapidly expanding their cultivation, processing, and retail footprints across state-legal markets, building strong regional brands and consumer loyalty, and establishing vertically integrated supply chains. This trend is creating formidable competitive barriers. When federal legalization eventually occurs, Cronos, a Canadian-based company largely restricted from direct U.S. THC market participation due to current federal laws, will likely face a deeply entrenched, well-capitalized, and experienced domestic industry that has already captured significant market share. This could severely impede Cronos's ability to effectively enter and compete in the crucial U.S. market, despite its strategic partnership with Altria, effectively limiting its most significant growth opportunity.
AI Analysis | Feedback
The Cronos Group (CRON) operates as a global cannabinoid company, focusing on the research, technology, and development of a diverse portfolio of cannabis products. Their main products include dried flowers, cannabis seeds, cannabis plants, cannabis extracts, cannabis topicals, and cannabis edibles, catering to both adult-use and medical consumers.
The company primarily operates in Canada and Israel, with a distribution agreement in Germany. While Cronos has wound down its direct U.S. operations, it continues to focus on global opportunities and prepares for the potential opening of the U.S. THC market in the future.
The addressable markets for Cronos Group's main products and services are sizable across various regions:
- Global Cannabis Market: The global legal cannabis market was estimated at USD 69.78 billion in 2024 and is projected to reach USD 216.76 billion by 2033, growing at a compound annual growth rate (CAGR) of 13.49% from 2025 to 2033. Another estimate placed the global cannabis market size at USD 41.95 billion in 2024, projected to grow to USD 290.73 billion by 2033, with a CAGR of 24% from 2025-2033. A separate report valued the global cannabis market at USD 43.72 billion in 2022, with projections to grow to USD 444.34 billion by 2030, exhibiting a CAGR of 34.03%.
- North America Legal Cannabis Market: This market was valued at approximately USD 44.83 billion in 2024 and is estimated to reach USD 354.82 billion by 2033, with a CAGR of 24.55% from 2025-2033. Other sources indicate a North America legal cannabis market size of USD 36.70 billion in 2023, with projections to grow to USD 82.18 billion by 2030 at a CAGR of 11.9%. North America held the largest market share in the global cannabis market in 2024, accounting for 71.69% of the revenue.
- U.S. Cannabis Market: The U.S. cannabis market size was estimated at USD 38.50 billion in 2024 and is expected to reach USD 76.39 billion by 2030, growing at a CAGR of 11.51% from 2025 to 2030. Retail sales in the U.S. cannabis industry are projected to exceed USD 32 billion in 2024 and could grow to USD 55 billion by 2030. Another estimate for the U.S. cannabis market revenue is USD 40.7 billion in 2024, with an expectation to reach USD 74.6 billion by 2032 at a CAGR of 6.8% from 2025.
- Canada Legal Cannabis Market: The legal cannabis market in Canada was valued at USD 3.25 billion in 2024 and is projected to grow at a CAGR of 12.0% from 2025 to 2030, reaching USD 5.79 billion. Recreational cannabis sales in Canada surpassed CA$5 billion (approximately USD 3.8 billion) in 2023. The total cannabis market in Canada is estimated to generate up to $7 billion in sales. The cannabis production industry in Canada is valued at $13.0 billion in 2025.
AI Analysis | Feedback
Cronos Group (CRON) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market dynamics:- Increased Flower Production Capacity from GrowCo Expansion: The completion of the Phase 2 expansion at Cronos GrowCo is a significant driver, with an anticipated 70% increase in flower production capacity. This expansion is expected to resolve supply constraints and significantly boost flower sales in 2026.
- Expansion and Strong Performance in International Markets: Cronos is focused on global expansion, having already expanded its distribution network to seven countries. The company has demonstrated strong performance in Israel, where its PEACE NATURALS® brand leads the medical cannabis market and patient count is growing. Traction with proprietary genetics in markets like Germany and the UK is also contributing to international growth.
- New Product Launches and Brand Strength in the Canadian Market: The Spinach® brand remains a strong performer in Canada, consistently ranking as a top brand for flower, vapes, and edibles. New product introductions, such as liquid diamond-infused gummies and limited-edition seasonal flavors, are expected to fuel continued revenue growth within the existing Canadian market.
- Strategic Investment in Innovation and High-Growth Opportunities: Management has highlighted a commitment to investing in innovation and global expansion, particularly in high-growth markets. This strategic focus aims to leverage the company's strong balance sheet to pursue opportunities that enhance its market position and product offerings.
AI Analysis | Feedback
Share Repurchases
- Cronos Group announced a share repurchase program of up to $50 million on May 8, 2025, authorized to repurchase up to 19,270,951 shares (5% of its issued shares) until May 13, 2026.
- During the nine months ended September 30, 2025, the company repurchased 2,792,813 common shares for $5,471.
- In Q3 2025, the company repurchased 917,862 common shares for $1,859.
Share Issuance
- As of November 3, 2025, Cronos Group had 382,893,267 common shares issued and outstanding.
- The number of outstanding shares increased from 0.35 billion at the end of 2020 to 0.38 billion at the end of 2025.
Inbound Investments
- Altria Group Inc. made a significant strategic investment of approximately $1.8 billion (C$2.4 billion) for a 45% equity stake in Cronos Group in 2019, providing substantial capital for global expansion and R&D.
- Cronos Group maintained a strong balance sheet with $824 million in cash equivalents and short-term investments as of Q3 2025, largely attributed to the initial investment by Altria.
Outbound Investments
- In July 2025, Cronos Group invested $18.5 million (C$30 million) in High Tide Inc. through a five-year junior secured convertible loan.
- In connection with the High Tide investment, Cronos also received a five-year common share purchase warrant exercisable for up to 3,840,000 common shares of High Tide.
- On June 20, 2024, Cronos made an additional investment in Cronos Growing Company Inc. ("Cronos GrowCo") to fund the expansion of cultivation operations and gained majority control, consolidating GrowCo's results as of July 1, 2024.
Capital Expenditures
- Cronos Group is expanding its Cronos GrowCo facilities to address flower supply constraints, with capital expenditures expected to remain elevated.
- The Cronos GrowCo expansion is anticipated to increase flower production capacity by 70%, with sales from this expansion commencing in Fall 2025.
- Capital expenditures for Q3 2025 amounted to $4.6 million.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to CRON. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.1% | 21.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -6.7% | -6.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 16.7% | 16.7% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 11.8% | 11.8% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Cronos
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 51.32 |
| Mkt Cap | 158.8 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.4% |
| Rev Chg 3Y Avg | 3.2% |
| Rev Chg Q | 8.3% |
| QoQ Delta Rev Chg LTM | 2.0% |
| Op Mgn LTM | 12.1% |
| Op Mgn 3Y Avg | 11.9% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 18.5% |
| CFO/Rev 3Y Avg | 17.1% |
| FCF/Rev LTM | 11.6% |
| FCF/Rev 3Y Avg | 12.1% |
Price Behavior
| Market Price | $2.66 | |
| Market Cap ($ Bil) | 1.0 | |
| First Trading Date | 02/27/2018 | |
| Distance from 52W High | -18.7% | |
| 50 Days | 200 Days | |
| DMA Price | $2.58 | $2.25 |
| DMA Trend | up | indeterminate |
| Distance from DMA | 3.1% | 18.4% |
| 3M | 1YR | |
| Volatility | 60.1% | 47.8% |
| Downside Capture | 72.11 | 51.83 |
| Upside Capture | 62.83 | 72.01 |
| Correlation (SPY) | 21.3% | 27.8% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.50 | 1.65 | 1.61 | 1.23 | 0.74 | 0.96 |
| Up Beta | 2.17 | 1.99 | 1.48 | 1.21 | 0.73 | 0.81 |
| Down Beta | 1.17 | 2.10 | 2.16 | 2.57 | 0.79 | 0.84 |
| Up Capture | 155% | 80% | 104% | 86% | 67% | 89% |
| Bmk +ve Days | 12 | 25 | 38 | 73 | 141 | 426 |
| Stock +ve Days | 11 | 21 | 30 | 59 | 110 | 323 |
| Down Capture | 128% | 171% | 159% | 54% | 77% | 106% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 7 | 19 | 30 | 57 | 122 | 383 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of CRON With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| CRON | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 36.4% | 15.1% | 17.8% | 72.1% | 8.6% | 4.4% | -8.3% |
| Annualized Volatility | 47.6% | 17.2% | 19.4% | 19.3% | 15.2% | 17.0% | 35.0% |
| Sharpe Ratio | 0.79 | 0.65 | 0.72 | 2.70 | 0.34 | 0.09 | -0.08 |
| Correlation With Other Assets | 13.0% | 27.7% | 0.5% | 12.9% | 20.7% | 24.5% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of CRON With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| CRON | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -19.6% | 8.4% | 14.7% | 18.7% | 11.5% | 4.6% | 30.8% |
| Annualized Volatility | 58.0% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.7% |
| Sharpe Ratio | -0.15 | 0.40 | 0.70 | 0.97 | 0.50 | 0.16 | 0.57 |
| Correlation With Other Assets | 22.8% | 34.5% | 4.0% | 9.3% | 25.4% | 20.8% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of CRON With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| CRON | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -12.6% | 9.9% | 14.8% | 15.3% | 7.0% | 5.3% | 69.2% |
| Annualized Volatility | 68.2% | 16.6% | 18.0% | 14.7% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.10 | 0.49 | 0.71 | 0.86 | 0.32 | 0.22 | 0.90 |
| Correlation With Other Assets | 25.6% | 33.1% | 4.0% | 11.8% | 24.5% | 16.1% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/6/2025 | 0.8% | 3.7% | 0.8% |
| 8/7/2025 | 8.1% | 24.8% | 19.0% |
| 5/8/2025 | 8.1% | 11.4% | 7.0% |
| 2/27/2025 | 8.1% | 9.7% | -1.1% |
| 11/12/2024 | 14.7% | 3.6% | -1.0% |
| 8/8/2024 | 4.5% | 5.9% | -3.6% |
| 5/9/2024 | 10.5% | 12.4% | -5.8% |
| 2/29/2024 | -8.0% | -13.3% | 15.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 10 | 9 |
| # Negative | 10 | 12 | 13 |
| Median Positive | 8.1% | 10.5% | 10.1% |
| Median Negative | -6.7% | -7.4% | -5.8% |
| Max Positive | 16.7% | 28.5% | 55.8% |
| Max Negative | -15.9% | -17.0% | -22.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11062025 | 10-Q 9/30/2025 |
| 6302025 | 8072025 | 10-Q 6/30/2025 |
| 3312025 | 5082025 | 10-Q 3/31/2025 |
| 12312024 | 2272025 | 10-K 12/31/2024 |
| 9302024 | 11122024 | 10-Q 9/30/2024 |
| 6302024 | 8082024 | 10-Q 6/30/2024 |
| 3312024 | 5092024 | 10-Q 3/31/2024 |
| 12312023 | 2292024 | 10-K 12/31/2023 |
| 9302023 | 11082023 | 10-Q 9/30/2023 |
| 6302023 | 8082023 | 10-Q 6/30/2023 |
| 3312023 | 5092023 | 10-Q 3/31/2023 |
| 12312022 | 2282023 | 10-K 12/31/2022 |
| 9302022 | 11072022 | 10-Q 9/30/2022 |
| 6302022 | 8092022 | 10-Q 6/30/2022 |
| 3312022 | 5102022 | 10-Q 3/31/2022 |
| 12312021 | 3012022 | 10-K 12/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.